Investment Analysts’ Weekly Ratings Changes for NeoGenomics (NEO)

Several analysts have recently updated their ratings and price targets for NeoGenomics (NASDAQ: NEO):

• 7/15/2026 – NeoGenomics had its “buy” rating reaffirmed by TD Cowen.
• 7/14/2026 – NeoGenomics was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 6/29/2026 – NeoGenomics was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 6/27/2026 – NeoGenomics was upgraded by Wall Street Zen from “hold” to “buy”.
• 6/8/2026 – NeoGenomics was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 5/21/2026 – NeoGenomics was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.

Insider Activity at NeoGenomics

In related news, Director Lynn A. Tetrault sold 5,307 shares of the business’s stock in a transaction on Tuesday, June 9th. The shares were sold at an average price of $11.29, for a total value of $59,916.03. Following the sale, the director owned 91,422 shares of the company’s stock, valued at $1,032,154.38. The trade was a 5.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 1.10% of the company’s stock.

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.